tetano
Editor, Senior Moderator
Front Immunol
. 2022 Oct 3;13:965171.
doi: 10.3389/fimmu.2022.965171. eCollection 2022.
Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study
Annamaria Mascolo[SUP] 1 2 [/SUP], Gabriella di Mauro[SUP] 1 2 3 [/SUP], Federica Fraenza[SUP] 1 2 [/SUP], Mario Gaio[SUP] 1 2 [/SUP], Alessia Zinzi[SUP] 1 2 [/SUP], Ciro Pentella[SUP] 1 2 [/SUP], Francesco Rossi[SUP] 1 2 [/SUP], Annalisa Capuano[SUP] 1 2 [/SUP], Liberata Sportiello[SUP] 1 2 [/SUP]
Affiliations
Abstract
Introduction: Although the European Medicines Agency (EMA) encourage coronavirus disease 2019 (COVID-19) vaccination in pregnant women, the scientific evidence supporting the use of COVID-19 vaccines during pregnancy is still limited.
Aim: We aimed to investigate adverse events following immunization (AEFI) with COVID-19 vaccines during pregnancy.
Methods: We retrieved Individual Case Safety Reports (ICSRs) related to the use of COVID-19 vaccines during pregnancy from the EudraVigilance database for the year 2021. We analyzed AEFI related to the mother and fetus/newborn. The reporting odds ratio (ROR) was computed to compare the reporting probability of spontaneous abortion between COVID-19 vaccines.
Results: During the study period, among 1,315,315 ICSRs related to COVID-19 vaccines, we retrieved 3,252 (0.25%) reports related to the use in pregnancy. More than half (58.24%) of ICSRs were submitted by non-healthcare professionals. Although the majority (87.82%) of ICSRs concerned serious AEFI, their outcomes were mostly favorable. In this study, 85.0% of total ICSRs referred to pregnant women (n = 2,764), while 7.9% referred to fetuses/newborns (n = 258). We identified 16,569 AEFI. Moreover, 55.16% were AEFI not related to pregnancy (mostly headache, pyrexia, and fatigue), while 17.92% were pregnancy-, newborn-, or fetus-related AEFI. Among pregnancy-related AEFI, the most reported was spontaneous abortion. Messenger RNA (mRNA) vaccines had a lower reporting probability of spontaneous abortion than viral vector-based vaccines (ROR 0.80, 95% CI 0.69-0.93). Moderna and Oxford-AstraZeneca vaccines had a higher reporting probability of spontaneous abortion (ROR 1.2, 95% CI 1.05-1.38 and ROR 1.26, 95% CI 1.08-1.47, respectively), while a lower reporting probability was found for Pfizer-BioNTech vaccine compared with all other COVID-19 vaccines (ROR 0.73, 95% CI 0.64-0.84). In addition, 5.8% of ICSRs reported a fatal outcome.
Conclusions: No strong insight of unknown AEFI associated with COVID-19 vaccination in pregnant women was observed. Considering the high risk associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, our analysis suggests that the benefits of COVID-19 vaccines during pregnancy outweigh the possible risks. However, it is important to continue monitoring the safety profile of COVID-19 vaccines in this subpopulation.
Keywords: COVID-19 vaccines; adverse events following immunization; database; maternal exposure during pregnancy; pharmacovigilance; pregnant women.
. 2022 Oct 3;13:965171.
doi: 10.3389/fimmu.2022.965171. eCollection 2022.
Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study
Annamaria Mascolo[SUP] 1 2 [/SUP], Gabriella di Mauro[SUP] 1 2 3 [/SUP], Federica Fraenza[SUP] 1 2 [/SUP], Mario Gaio[SUP] 1 2 [/SUP], Alessia Zinzi[SUP] 1 2 [/SUP], Ciro Pentella[SUP] 1 2 [/SUP], Francesco Rossi[SUP] 1 2 [/SUP], Annalisa Capuano[SUP] 1 2 [/SUP], Liberata Sportiello[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36263025
- PMCID: PMC9574088
- DOI: 10.3389/fimmu.2022.965171
Abstract
Introduction: Although the European Medicines Agency (EMA) encourage coronavirus disease 2019 (COVID-19) vaccination in pregnant women, the scientific evidence supporting the use of COVID-19 vaccines during pregnancy is still limited.
Aim: We aimed to investigate adverse events following immunization (AEFI) with COVID-19 vaccines during pregnancy.
Methods: We retrieved Individual Case Safety Reports (ICSRs) related to the use of COVID-19 vaccines during pregnancy from the EudraVigilance database for the year 2021. We analyzed AEFI related to the mother and fetus/newborn. The reporting odds ratio (ROR) was computed to compare the reporting probability of spontaneous abortion between COVID-19 vaccines.
Results: During the study period, among 1,315,315 ICSRs related to COVID-19 vaccines, we retrieved 3,252 (0.25%) reports related to the use in pregnancy. More than half (58.24%) of ICSRs were submitted by non-healthcare professionals. Although the majority (87.82%) of ICSRs concerned serious AEFI, their outcomes were mostly favorable. In this study, 85.0% of total ICSRs referred to pregnant women (n = 2,764), while 7.9% referred to fetuses/newborns (n = 258). We identified 16,569 AEFI. Moreover, 55.16% were AEFI not related to pregnancy (mostly headache, pyrexia, and fatigue), while 17.92% were pregnancy-, newborn-, or fetus-related AEFI. Among pregnancy-related AEFI, the most reported was spontaneous abortion. Messenger RNA (mRNA) vaccines had a lower reporting probability of spontaneous abortion than viral vector-based vaccines (ROR 0.80, 95% CI 0.69-0.93). Moderna and Oxford-AstraZeneca vaccines had a higher reporting probability of spontaneous abortion (ROR 1.2, 95% CI 1.05-1.38 and ROR 1.26, 95% CI 1.08-1.47, respectively), while a lower reporting probability was found for Pfizer-BioNTech vaccine compared with all other COVID-19 vaccines (ROR 0.73, 95% CI 0.64-0.84). In addition, 5.8% of ICSRs reported a fatal outcome.
Conclusions: No strong insight of unknown AEFI associated with COVID-19 vaccination in pregnant women was observed. Considering the high risk associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, our analysis suggests that the benefits of COVID-19 vaccines during pregnancy outweigh the possible risks. However, it is important to continue monitoring the safety profile of COVID-19 vaccines in this subpopulation.
Keywords: COVID-19 vaccines; adverse events following immunization; database; maternal exposure during pregnancy; pharmacovigilance; pregnant women.